Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review

  • ID: 4281463
  • SWOT Analysis
  • 44 pages
  • GlobalData
  • Karyopharm Therapeutics Inc
1 of 5

FEATURED COMPANIES

  • Omeros Corp
  • Stemline Therapeutics Inc
  • MORE
Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Omeros Corp
  • Stemline Therapeutics Inc
  • MORE
Section 1 - About the Company
  • Karyopharm Therapeutics Inc - Key Facts
  • Karyopharm Therapeutics Inc - Key Employees
  • Karyopharm Therapeutics Inc - Key Employee Biographies
  • Karyopharm Therapeutics Inc - Major Products and Services
  • Karyopharm Therapeutics Inc - History
  • Karyopharm Therapeutics Inc - Company Statement
  • Karyopharm Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Karyopharm Therapeutics Inc - Business Description
  • R&D Overview
  • Karyopharm Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Karyopharm Therapeutics Inc - Strengths
  • Karyopharm Therapeutics Inc - Weaknesses
  • Karyopharm Therapeutics Inc - Opportunities
  • Karyopharm Therapeutics Inc - Threats
  • Karyopharm Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
  • Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
  • Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
  • May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
  • Apr 03, 2017: Karyopharm Announces Management Change
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Karyopharm Therapeutics Inc, Key Facts
  • Karyopharm Therapeutics Inc, Key Employees
  • Karyopharm Therapeutics Inc, Key Employee Biographies
  • Karyopharm Therapeutics Inc, Major Products and Services
  • Karyopharm Therapeutics Inc, History
  • Karyopharm Therapeutics Inc, Subsidiaries
  • Karyopharm Therapeutics Inc, Key Competitors
  • Karyopharm Therapeutics Inc, Ratios based on current share price
  • Karyopharm Therapeutics Inc, Annual Ratios
  • Karyopharm Therapeutics Inc, Annual Ratios
  • Karyopharm Therapeutics Inc, Interim Ratios
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Karyopharm Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Karyopharm Therapeutics Inc, Performance Chart (2013 - 2017)
  • Karyopharm Therapeutics Inc, Ratio Charts
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • TetraLogic Pharmaceuticals
  • Stemline Therapeutics Inc
  • Omeros Corp
  • Imprimis Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll